Terms: = Prostate cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12
296 results:
1. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
2. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
[TBL] [Abstract] [Full Text] [Related]
3. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
Yamada Y; Fujii Y; Kakutani S; Kimura N; Sugimoto K; Hakozaki Y; Sugihara T; Takeshima Y; Kawai T; Nakamura M; Kamei J; Taguchi S; Akiyama Y; Sato Y; Yamada D; Urabe F; Miyazaki H; Enomoto Y; Fukuhara H; Nakagawa T; Fujimura T; Kume H
Sci Rep; 2024 Mar; 14(1):7607. PubMed ID: 38556562
[TBL] [Abstract] [Full Text] [Related]
4. Assessment of the Surgical Oncology Case Volume Within the Public Sector in Tanzania.
Brand NR; Akoko L; Kotecha V; Mwakyembe T; Mwashambwa M; Hamid R; Hando D; Komba C; Mwanga A; Mbele P; Itule P; Jackson J; Misidai M; Gaskill C; Ozgediz D
JCO Glob Oncol; 2024 Mar; 10():e2300316. PubMed ID: 38452305
[TBL] [Abstract] [Full Text] [Related]
5. Triglyceride-glucose index is a predictor of the risk of prostate cancer: a retrospective study based on a transprostatic aspiration biopsy population.
Zhou Y; Li T; Muheiyati G; Duan Y; Xiao S; Gao Y; Tao N; An H
Front Endocrinol (Lausanne); 2023; 14():1280221. PubMed ID: 38260162
[TBL] [Abstract] [Full Text] [Related]
6. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive prostate cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract] [Full Text] [Related]
7. RhoU forms homo-oligomers to regulate cellular responses.
Clayton NS; Hodge RG; Infante E; Alibhai D; Zhou F; Ridley AJ
J Cell Sci; 2024 Jan; 137(2):. PubMed ID: 38180080
[TBL] [Abstract] [Full Text] [Related]
8. Air quality and cancer risk in the All of Us Research Program.
Craver A; Luo J; Kibriya MG; Randorf N; Bahl K; Connellan E; Powell J; Zakin P; Jones RR; Argos M; Ho J; Kim K; Daviglus ML; Greenland P; Ahsan H; Aschebrook-Kilfoy B
Cancer Causes Control; 2024 May; 35(5):749-760. PubMed ID: 38145439
[TBL] [Abstract] [Full Text] [Related]
9. Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
Donners R; Figueiredo I; Westaby D; Koh DM; Tunariu N; Carreira S; de Bono JS; Fotiadis N
Cancer Imaging; 2023 Dec; 23(1):121. PubMed ID: 38102655
[TBL] [Abstract] [Full Text] [Related]
10. Leukocyte Telomere Length and the Risk of prostate cancer and Benign Prostatic Hyperplasia: Insights From UK Biobank and Mendelian Randomization Study.
Lv K; Wu Y; Yang G; Hao X; Huang S; Song T; Yuan Q
J Gerontol A Biol Sci Med Sci; 2024 Mar; 79(3):. PubMed ID: 38085929
[TBL] [Abstract] [Full Text] [Related]
11. Developing and validating utility parameters to establish patient-reported outcome-based perioperative symptom management in patients undergoing prostatectomy: a multicentre, prospective, observational cohort study protocol.
Li J; Chen T; Gao J; Peng F; Gu T; Jin B
BMJ Open; 2023 Aug; 13(8):e074763. PubMed ID: 37553190
[TBL] [Abstract] [Full Text] [Related]
12. AR activates YAP/TAZ differentially in prostate cancer.
Salem O; Jia S; Qian BZ; Hansen CG
Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37385752
[TBL] [Abstract] [Full Text] [Related]
13. Mortality Benefit of a Blood-Based Biomarker Panel for Lung cancer on the Basis of the prostate, Lung, Colorectal, and Ovarian Cohort.
Irajizad E; Fahrmann JF; Marsh T; Vykoukal J; Dennison JB; Long JP; Do KA; Feng Z; Hanash S; Ostrin EJ
J Clin Oncol; 2023 Sep; 41(27):4360-4368. PubMed ID: 37379494
[TBL] [Abstract] [Full Text] [Related]
14. After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancers.
Hoffman RM
Ann Intern Med; 2023 Apr; 176(4):JC44. PubMed ID: 37011398
[TBL] [Abstract] [Full Text] [Related]
15. Plexin-B1 Mutation Drives Metastasis in prostate cancer Mouse Models.
Shorning B; Trent N; Griffiths DF; Worzfeld T; Offermanns S; Smalley MJ; Williamson M
Cancer Res Commun; 2023 Mar; 3(3):444-458. PubMed ID: 36936664
[TBL] [Abstract] [Full Text] [Related]
16. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract] [Full Text] [Related]
17. Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for prostate and Liver cancer.
Giráldez-Pérez RM; Grueso E; Montero-Hidalgo AJ; Luque RM; Carnerero JM; Kuliszewska E; Prado-Gotor R
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555216
[TBL] [Abstract] [Full Text] [Related]
18. Association between working hours and cancer risk in Japan: The Japan public health center-based prospective study.
Hattori K; Sobue T; Zha L; Kitamura T; Shimomura Y; Iwasaki M; Inoue M; Yamaji T; Tsugane S; Sawada N
J Occup Health; 2022 Jan; 64(1):e12375. PubMed ID: 36502469
[TBL] [Abstract] [Full Text] [Related]
19. Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the rhoa/ROCK/NLRP3 pathway.
Liu Z; Zhu X; Xu C; Min F; Yu G; Chen C
Drug Dev Res; 2023 Feb; 84(1):36-44. PubMed ID: 36461611
[TBL] [Abstract] [Full Text] [Related]
20. A review on the role of PCGEM1 lncRNA in cancer.
Ghafouri-Fard S; Khoshbakht T; Hussen BM; Baniahmad A; Taheri M; Mokhtari M
Pathol Res Pract; 2022 Dec; 240():154223. PubMed ID: 36403313
[TBL] [Abstract] [Full Text] [Related]
[Next]
